Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Ubiquitin signaling in tumor-associated macrophage reprogramming: mechanisms and therapeutic opportunities in cancers.

Created on 17 Oct 2026

Authors

Xudong Li, Yaomei Wang, Ruochen Xu, Ziheng Qian, Meimei Yan, Mengya Gao, Zexing Liu, Yun Zhai, Lijie Wang, Yushan Cui, Lina Liu, Yongping Song, Zhilei Bian, Linping Xu, Wei Li, Baijun Fang

Published in

Biomarker research. Volume 14. Issue 1. Oct 16, 2026. Epub Oct 16, 2026.

Abstract

Tumor-associated macrophages (TAMs) are key regulators of tumor progression and immune suppression within the tumor microenvironment (TME). Emerging evidence identifies ubiquitination, a dynamic post-translational modification that regulates protein stability, localization, and signaling activity, as a critical determinant of TAM function. Ubiquitin signaling orchestrates macrophage inflammatory responses, metabolic reprogramming, and tumor cell-immune cell crosstalk through coordinated actions of ubiquitin-activating enzymes, ubiquitin-conjugating enzymes, ubiquitin-protein ligases (E3s), and deubiquitinating enzymes (DUBs). Dysregulation of these ubiquitin networks fosters an immunosuppressive microenvironment, thereby promoting tumor growth, metastasis, and therapeutic resistance. In this review, we summarize recent advances in the role of ubiquitination in TAM biology, focusing on key E3 ubiquitin ligases and DUBs in TAM immunity. We further discuss emerging ubiquitin-dependent signaling pathways that integrate metabolic and inflammatory cues within TAMs. Finally, we highlight the therapeutic potential of targeting ubiquitination machinery to reprogram TAMs and remodel the TME. Collectively, this review provides a comprehensive framework for understanding ubiquitin-mediated regulation of TAM function and offers novel perspectives for developing ubiquitination-based cancer immunotherapies.

PMID:
42888457
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement